BioStem Technologies Past Earnings Performance
Past criteria checks 4/6
BioStem Technologies has been growing earnings at an average annual rate of 58.7%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 137.5% per year. BioStem Technologies's return on equity is 69.4%, and it has net margins of 7.5%.
Key information
58.7%
Earnings growth rate
53.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 137.5% |
| Return on equity | 69.4% |
| Net Margin | 7.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioStem Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 210 | 16 | 175 | 1 |
| 30 Jun 24 | 131 | 8 | 111 | 0 |
| 31 Mar 24 | 58 | -1 | 53 | 0 |
| 31 Dec 23 | 17 | -8 | 22 | 0 |
| 30 Sep 23 | 6 | -10 | 14 | 0 |
| 30 Jun 23 | 4 | -11 | 13 | 0 |
| 31 Mar 23 | 5 | -8 | 11 | 0 |
| 31 Dec 22 | 7 | -7 | 10 | 0 |
| 30 Sep 22 | 7 | -4 | 7 | 0 |
| 30 Jun 22 | 7 | -4 | 7 | 0 |
| 31 Mar 22 | 6 | -4 | 7 | 0 |
| 31 Dec 21 | 4 | -1 | 4 | 0 |
| 30 Jun 18 | 0 | -4 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 5 | 0 |
| 31 Dec 17 | 0 | -5 | 5 | 0 |
| 30 Sep 17 | 0 | -3 | 3 | 0 |
| 30 Jun 17 | 0 | -4 | 4 | 0 |
| 31 Mar 17 | 1 | -3 | 4 | 0 |
| 31 Dec 16 | 1 | -4 | 4 | 0 |
| 30 Sep 16 | 1 | -6 | 6 | 0 |
| 30 Jun 16 | 1 | -4 | 4 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
| 31 Dec 15 | 0 | -2 | 2 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
Quality Earnings: BSEM has high quality earnings.
Growing Profit Margin: BSEM became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BSEM has become profitable over the past 5 years.
Accelerating Growth: BSEM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BSEM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BSEM's Return on Equity (69.4%) is considered outstanding.